Axsome Therapeutics Inc AXSM
๐ Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2015-11-19 |
| Shares Out. | 51,460,000 |
| Website | axsome.com/ โ |
| Phone | 12123323241 |
| Employees | 925 |
| Revenue | $191.2M |
| Gross Profit | $176.5M |
| Net Income | -$64.5M |
| Free Cash Flow | -$71.0M |
| Total Assets | $713.6M |
| Total Liabilities | $659.0M |
| Equity | $54.6M |
About Axsome Therapeutics Inc
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
Axsome Therapeutics Inc is a publicly traded company under the ticker symbol AXSM on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
๐ Analyst Ratings
27 analysts (2026-07-01)

